Related Experiment Videos
Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents
D J Chaplin1, G R Pettit, C S Parkins
1Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex.
Abstract:
We have assessed the vascular effects of vinblastine and four other tubulin binding agents (dolastatin 10, dolastatin 15, combretastatin A1 and combretastatin A4), which are awaiting clinical evaluation. All five agents induce a reduction in tumour blood flow as measured by uptake of RbCI 24 h post drug administration. The degree of reduction ranged from 50% with combretastatin A1 to 90% with dolastatin 10. These reductions were similar to that seen with flavone acetic acid (FAA) and indicate that antivascular effects are a common feature of tubulin binding agents. We subsequently evaluated whether the blood flow reductions, induced by FAA and vinblastine, could be used to enhance the activity of the bioreductive drug tirapazamine. Since the kinetics and extent of blood flow reductions induced by the agents is comparable, similar therapeutic response was expected. Potentiation was only evident with FAA, indicating that this effect is not directly related to killing of hypoxic tumour cells induced as a consequence of blood flow reduction.
Insights
Tubulin binding agents, including vinblastine, reduce tumor blood flow, a common antivascular effect. This vascular targeting did not universally enhance bioreductive drug efficacy, suggesting complex therapeutic interactions.
Area of Science:
- Oncology
- Pharmacology
- Vascular Biology
Background:
- Tubulin binding agents are a class of drugs with potential anticancer activity.
- Tumor vasculature is a key target for cancer therapies.
- Antivascular effects of drugs can impact tumor oxygenation and treatment response.
Purpose of the Study:
- To assess the vascular effects of vinblastine and other tubulin binding agents.
- To investigate if tumor blood flow reduction enhances the activity of the bioreductive drug tirapazamine.
- To determine the relationship between antivascular effects and therapeutic potentiation.
Main Methods:
- Assessed tumor blood flow reduction using RbCl uptake in response to vinblastine and four other tubulin binding agents.
- Compared the antivascular effects of these agents with flavone acetic acid (FAA).
- Evaluated the potentiation of tirapazamine activity by FAA and vinblastine-induced blood flow reductions.
Main Results:
- All five tubulin binding agents reduced tumor blood flow, with reductions ranging from 50% to 90%.
- These reductions were comparable to those induced by flavone acetic acid (FAA).
- Only FAA-induced blood flow reduction potentiated tirapazamine activity, indicating the effect is not solely due to hypoxia.
Conclusions:
- Antivascular effects are a common feature of tubulin binding agents.
- The ability to enhance bioreductive drug activity is agent-specific and not solely dependent on the extent of tumor blood flow reduction.
- Further research is needed to elucidate the mechanisms underlying the differential potentiation of tirapazamine by antivascular agents.